IP Library Granted Patent US 10,111,913
Granted Patent B2
US 10,111,913 · App. 15/403,823 · Granted Oct 30, 2018

Method of reducing the likelihood of skin cancer in an individual human being

Inventor: Joseph E. Kovarik (Englewood, CO)
A61K35/74A61K31/58A61K31/715A61K38/1709A61K38/1758A61K2035/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,111,913
App. No.
15/403,823
Granted
Oct 30, 2018
Kind
B2
Abstract

Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome.

Claims (8)

1. A method of reducing the likelihood of skin cancer in an individual human being, said method comprising: administering a therapeutically effective amount of a bacterial formulation comprising Nitrosomonas eutropha adapted to produce p53 said bacterial formulation comprising a lotion, ointment or gel adapted to be rubbed onto a region of an individual's skin.

2. The method as set forth in claim 1 , wherein the region of the skin is the scalp.

3. The method as set forth in claim 1 , further comprising administering to the individual's skin a prebiotic that comprises a nutrient source for the Nitrosomonas eutropha.

4. The method as set forth in claim 1 , further comprising administering to the individual's skin a prebiotic that comprises a nutrient source for the bacteria in the bacterial formulation that is assimilated by the bacteria.

5. The method as set forth in claim 1 , wherein the bacterial formulation further includes Propionibacterium bacteria.

6. The method as set forth in claim 1 , further comprising administering to the skin an extract derived from a helminth selected from the group consisting of Capillaria hepatica, Dicrocoelium dendriticum, Ascaris lumbricoides, Enterobius vermicularis, Trichuris trichiura, Ancylostoma duodenale, Necator americanus, Strongyloides stercoralis, Haemonchus contortus , and Trichinella spiralis.

7. The method as set forth in claim 1 , wherein the bacterial formulation includes at least one arabinogalactan.

8. The method as set forth in claim 1 , wherein the bacterial formulation includes L. johnsonii.

Assignments (2)
SECURITY INTEREST Recorded Jul 21, 2026
From: SEED HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A., AS LENDER
Reel/Frame 076028/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2022
From: KOVARIK, JOE
To: SEED HEALTH, INC.
Reel/Frame 059690/0210 →
Continuity (23)
Continuation In Part 14752192 · Jun 26, 2015
Continuation In Part 14225503 · Mar 26, 2014
Continuation 13367052 · Feb 6, 2012
Continuation 15403823
Continuation In Part 15270034 · Sep 20, 2016
Continuation In Part 14954074 · Nov 30, 2015
Continuation In Part 14574517 · Dec 18, 2014
Continuation In Part 15228454 · Aug 4, 2016
Continuation In Part 15403823
Continuation In Part 14611458 · Feb 2, 2015
Continuation In Part 14502097 · Sep 30, 2014
Continuation 14307651 · Jun 18, 2014
Continuation In Part 14079054 · Nov 13, 2013
Continuation 13425913 · Mar 21, 2012
Provisional Application 62296186 · Feb 17, 2016
Provisional Application 61439652 · Feb 4, 2011
Provisional Application 61556023 · Nov 4, 2011
Provisional Application 62072476 · Oct 30, 2014
Provisional Application 62053926 · Sep 23, 2014
Provisional Application 62104855 · Jun 20, 2014
Provisional Application 61919297 · Dec 20, 2013
Provisional Application 61467767 · Mar 25, 2011
Related Publication 20170119827A1 · May 4, 2017
Cited By (8)
US 12,246,043 US 12,257,272 US 12,279,989 US 12,318,411 US 12,318,414 US 12,329,783 US 12,357,662 US 12,533,312